If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Fibromyalgia, Decision Resources is offering an exclusive analyst call entitled Despite Safety Concerns, Sodium Oxybate is Poised for Approval in the U.S. for Fibromyalgia: Will It See Any Uptake in Primary Care? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Following Jazz Pharmaceuticals’ application late last year for U.S. regulatory approval of sodium oxybate, Decision Resources surveyed 30 U.S. primary care physicians (PCPs) and 30 U.S. rheumatologists to determine, among other factors, how a drug with a potential for abuse will be prescribed in the treatment of fibromyalgia and whether it will be prescribed at all in the primary care setting. Although sodium oxybate carries significant risk for severe adverse events, abuse and illicit use, it is nonetheless poised to garner sales of as much as $400 million in 2018 in the world’s major pharmaceutical markets, owing to its premium price. Due to the robust efficacy it has demonstrated in late stage clinical trials, thought leaders are impressed with sodium oxybate’s effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue. However, the extent to which the drug will be prescribed by specialists and primary care physicians remains to be seen. This 15-minute analyst call, presented by Analyst Andrea Buurma, B.A., will answer the following questions:
Ms. Buurma will conduct a live Q & A session after the presentation. Registration Despite Safety Concerns, Sodium Oxybate is Poised for Approval in the U.S. for Fibromyalgia: Will It See Any Uptake in Primary Care? February 25, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Andrea Buurma is an analyst in the central nervous system disorders unit of Decision Resources. Prior to joining Decision Resources, Ms. Buurma received a B.A. degree, summa cum laude, from Boston University. At Boston University, Ms. Buurma conducted research on indole-3-acetic acid biosynthesis and camalexin production in Arabidopsis thaliana.